Bio-pharmaceutical company ANI Pharmaceuticals Inc (ANI or the Company) (Nasdaq: ANIP) reported on Wednesday that it has received US Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100mg.
ANI said its Trimethoprim Tablets are the generic version of the Reference Listed Drug (RLD) of the same established name.
Nikhil Lalwani, president and chief executive officer of ANI, stated: "As we continue to focus on bringing niche limited-competition products to market, we are pleased to announce the FDA approval and commercialization of Trimethoprim Tablets."
ANI aims to serve patients in need by developing, manufacturing and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial